



FORM PTO-14 PATENT AND TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: OC01626K	APPLICATION NO.: 10/666,424
		APPLICANT: Kamil Paruch et al.	
		FILING DATE: 9/19/2003	GROUP:

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL EP 0 778 277	06/11/1997	EPO			
	AM WO 02/06286	01/24/2002	PCT			
	AN WO 88/04298	06/16/1988	PCT			
	AO					
	AP					


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AQ	Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem</i> (1994), 224: 771-785.
	AR	Senderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>Journal of Clinical Oncology</i> (September 1998), 16(9): 2986-2999.
	AS	Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases CDC2, CDK2 and CDK5", <i>Eur. J. Biochem.</i> (1997), 243: 527-536.
	AT	Bible et al., "Cytotoxic Synergy Between Flavopiridol (NSC 649890, L86-8275) and Various Antineoplastic Agents: The Importance of Sequence of Administration", <i>Cancer Research</i> (August 15, 1997), 57: 3375-3380.
	AU	Shiota et al., "Synthesis and Structure- Activity Relationship of a New Series of Potent Angiotensin II Receptor Antagonists: Pyrazolo[1,5- α]pyrimidine Derivatives", <i>Chem. Pharm. Bull.</i> (1999), 47(7): 928-938.
	AV	Xasuo Makisumi, "Studies on the Azaindolizine Compounds. XI. Synthesis of 6,7-Disubstituted Pyrazolo[1,5- α]pyrimidines", <i>Chem. Pharm. Bull.</i> (1962), 10: 620-626.


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		ATTY. DOCKET NO.: OC01626K		APPLICATION NO.: 10/666,424				
		APPLICANT: Kamil Paruch et al.						
		FILING DATE: 09/19/2003		GROUP:				
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
	AA							
	AB							
	AC							
	AD							
	AE							
	AF							
	AG							
	AH							
	AI							
	AJ							
	AK							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
	AL	WO 2002 060492 A	08/08/2002	WIPO				
	AM							
	AN							
	AO							
	AP							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	AQ							
	AR							
	AS							
	AT							
	AU							
	AV							
EXAMINER		DATE CONSIDERED						
		3/7/06						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Sheet 2 of 2

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: OC01626K		APPLICATION NO.: 10/666,424			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				APPLICANT: Kamil Paruch et al.			
				FILING DATE: 09/19/2003			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AW						
	AX						
	AY						
	AZ						
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	BH	WO 02/10162	02/07/2002	WIPO			
	BI						
	BJ						
	BK						
	BL						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	BM	A. Sanderowicz et al., "Phase I Trial of Continuous Infusion Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Patients with Refractory Neoplasms", <i>J. Clin. Oncology</i> , 16 : 2986-2990 (1998).					
	BN	J. Vesely et al., "Inhibition of Cyclin-Dependent Kinases by Purine Analogues", <i>Eur. J. Biochem.</i> , 224 : 771-786 (1994).					
	BO	I. Meijer et al., "Biochemical and Cellular Effects of Roscovitine, a Potent and Selective Inhibitor of the Cyclin-Dependent Kinases cdc2, cdk2 and cdk5", <i>Eur. J. Biochem.</i> , 243 : 527-536 (1997).					
	BP	K. S. Kim et al., "Discovery of Aminothiazole Inhibitors of Cyclin-Dependent Kinase 2: Synthesis, X-ray Crystallographic Analysis, and Biological Activities", <i>J. Medicinal Chemistry</i> , 45 : 3905-3927 (2002).					
	BQ						
	BR						
EXAMINER 				DATE CONSIDERED 3/7/06			
*EXAMINER/ Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							